Primary rhabdomyosarcoma: An extremely rare and aggressive variant of male breast cancer

doi:10.12998/wjcc.v8.i19.4466

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5741)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

265

WORD

183

HTML

2722

Figures (1-4)

802

Tables (1-2)

389

Sum=4361

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

514

Download

866

Sum=1380

Oct 6, 2020 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Oct 6, 2020; 8(19): 4466-4474
Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4466

Table 1 Immunohistochemical markers used to confirm the rhabdomyosarcoma with neuroectodermal differentiation

Antibody	Clone	Dilution	Manufacturer	Retrieval	RMS comp	NED comp	Line of differentiation confirmed
VIM	V9	RTU	DAKO^/ Denmark	High pH	+	+	Mesenchymal origin
DESM	D33	RTU	DAKO	High pH	+	-	Myogenic origin
MYO	F5D	1:100	ImmunoLogic/Netherland	High pH	+	-	Rhabdomyosarcoma component
SA	Alpha Sr-1	1:100	DAKO	Citrate	+	-	Rhabdomyosarcoma component
NF	2F11	1:100	DAKO	Citrate	-	+	Neuroectodermal component
NSE	BBS/NC/V1-414	RTU	DAKO	High pH	-	+	Neuroectodermal component
CD99	12E7	RTU	DAKO	High pH	-	+	Neuroectodermal component

Comp: Component; DESM: Desmin; MYO: Myogenin; NED: Neuroectodermal; NF: Neurofilament; NSE: Neuron specific enolase; SA: Sarcomeric actin; RMS: Rhabdomyosarcoma; RTU: Ready to use; VIM: Vimentin.

Table 2 Immunohistochemical markers used for differential diagnosis of rhabdomyosarcoma with neuroectodermal differentiation, based on their negativity in the two components

Antibody	Clone	Dilution	Manufacturer	Retrieval	Line of differentiation ruled out
Pan-CK	AE1/AE3	RTU	ImmunoLogic^/ Netherland	High pH	Epithelial origin/carcinoma
EMA	E29	RTU	ImmunoLogic	High pH
CK7	OV-TL	RTU	A. Menarini/ Italy	High pH
p63	4A4	RTU	ImmunoLogic	High pH	Squamous cell differentiation
SMA	1A4	RTU	Cell Marque^/ Netherland	High pH	Leyomyosarcoma
CALd	4-CD	1:100	DAKO/ Denmark	Citrate	Leyomyosarcoma
CALr	DAK Calret-1	1:100	DAKO	High pH	Mesothelial origin
ER	1D5	RTU	Thermo Scientific/UK	High pH	Breast carcinoma
PR	PGR 312	RTU	Leica/UK	High pH	Breast carcinoma
S100 protein	polyclonal	1:6000	DAKO	Citrate	Melanoma
HMB45	HMB45	RTU	Cell Marque	Citrate	Melanoma
CD45/ LCA	UCHL-1	RTU	Immunologic	High pH	Lymphoma
CD3	F7.2.38	RTU	DAKO	High pH
CD20	L26	RTU	Cell Marque	High pH
CD31	JC70	RTU	A. Menarini	Citrate	Vascular origin
CD34	QBEnd10	RTU	DAKO	High pH	Vascular origin
CD68	KP1	RTU	Immunologic	Citrate	Histiocytic origin
SYN	DAK-Synap	RTU	DAKO	High pH	Neuroendocrine differentiation

CALd: Caldesmon; CALr: Calretinin; CK: Cytokeratin; EMA: Epithelial membrane antigen; ER: Estrogen receptor; HMB45: Human melanoma black 45; LCA: Leukocyte common antigen; PR: Progesteron receptor; RTU: Ready to use; SMA: Smooth muscle actin; SYN: Synaptophysin.

Citation: Satală CB, Jung I, Bara TJ, Simu P, Simu I, Vlad M, Szodorai R, Gurzu S. Primary rhabdomyosarcoma: An extremely rare and aggressive variant of male breast cancer. World J Clin Cases 2020; 8(19): 4466-4474
URL: https://www.wjgnet.com/2307-8960/full/v8/i19/4466.htm
DOI: https://dx.doi.org/10.12998/wjcc.v8.i19.4466